22 June 2021 | News
Atum Sales Plus will enhance customer engagement and drive higher revenue-based growth for the industry
Image Credit: shutterstock
Stratbeans, the provider of AI-based online learning solutions, has launched Atum Sales Plus, a new-age sales enablement solution powered by AI for the pharmaceuticals industry. The employment of Atum Sales Plus will equip the sales professionals in the pharma segment with better skills and technology, which would enhance their sales-readiness, leading to improved customer engagement and in turn, higher revenue generation.
The new sales enablement platform would allow faster onboarding of new sales team, provide remote coaching and practice opportunities, generate personalised training modules along with offering extensive AI-based performance support in the form of a reference library. All this would greatly enhance the efficiency of the sales personnel and enable them to deliver value-based selling experiences successfully.
Pradeip Agarwal, COO & Co-founder, Stratbeans, “Sales enablement is critical to ensure a healthy bottom line in these current unpredictable times. And, it is of utmost importance to give sellers the right technology in hand which could allow them to effectively spearhead sales and create maximum value and impact. Introduction of Atum Sales Plus is a milestone for us, and we look forward to making a valuable difference.”
Besides enhancing the selling skills and potential of the pharma field workforce, the employment of Atum Sales Plus would also enable the sales team to deliver tailor-made customer experiences and build compliant relationships, which is a key requirement of the industry.
Agarwal further adds, “At Stratbeans, innovation is our key mantra, and we are confident that the new sales enablement technology will empower sellers in the pharma segment to improve their operational efficiency, drive better sales and achieve maximum ROI.”
By providing up-to-date, real-time information on products and developments, the integration with Atum Sales Plus would also lead to a significant reduction of product launch times for the pharma companies.